Click Here to Register »

2017 Agenda

  • 7:30 am

  • Registration & Breakfast

  • 8:15 am

  • Co-chair’s Opening Remarks

    Axel Hoos
    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GlaxoSmithKline

    Patrick Hwu
    Patrick Hwu, MD

    Head, Division of Cancer Medicine, Department Chair, Melanoma Medical Oncology Department Chair, Sarcoma Medical Oncology, MD Anderson Cancer Center

    Ian McCaffery
    Ian McCaffery, PhD

    VP Translational Sciences, Corvus Pharmaceuticals


  • DE-RISKING OF COMBINATION IMMUNOTHERAPIES PLENARY SESSION

    Plenary Chair:

    Patrick Hwu
    Patrick Hwu, MD

    Head, Division of Cancer Medicine, Department Chair, Melanoma Medical Oncology Department Chair, Sarcoma Medical Oncology, MD Anderson Cancer Center

  • 8:30 am

  • Preclinical Models for Rational Combinations

    Ruslan Novosiadly
    Ruslan Novosiadly, MD, PhD

    Senior Research Advisor, Cancer Immunobiology, Biomarkers, Eli Lilly and Company


  • Immune Monitoring to Determine Efficacy of Combination Immunotherapy

    Lisa Butterfield
    Lisa Butterfield, PhD

    Professor of Medicine, Surgery and Immunology Director, UPCI Immunologic Monitoring and Cellular Products Laboratory / President, University of Pittsburgh / Society for Immunotherapy of Cancer (SITC)


  • Epigenetic Therapy Combinations with Immunotherapy

    jean pierre issa
    Jean-Pierre Issa, MD

    Director, Fels Institute for Cancer Research and Molecular Biology / Professor of Medicine, Lewis Katz School of Medicine, Temple University


  • Morning Networking Break


  • Use of Master Protocols: Basket Trials and Umbrellas

    Roger Dansey
    Roger Dansey, MD

    SVP Global Clinical Development Oncology, Merck Research Laboratories


  • Prioritizing Combinations using a Human Phenotypic Model for Drug Development


    Parker Cassidy

    Chief Commercial Officer, Mitra Biotech


  • Rational Combinations of Targeted and Immunotherapy

    Patrick Hwu
    Patrick Hwu, MD

    Head, Division of Cancer Medicine, Department Chair, Melanoma Medical Oncology Department Chair, Sarcoma Medical Oncology, MD Anderson Cancer Center

  • 12:40 pm

  • Lunch


  • IMMUNO RESISTANCE – DRIVERS FOR COMBINATION THERAPY

    Plenary Chair:

    Roger Lo
    Roger Lo, MD, PhD

    Professor, Medicine & Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA

  • 1:40 pm

  • Resistance Mechanisms to Checkpoint Blockade in Melanoma

    Roger Lo
    Roger Lo, MD, PhD

    Professor, Medicine & Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA


  • Mutations and Sensitivity & Resistance to Immunotherapy

    Laszlo Radvanyi
    Laszlo Radvanyi, PhD

    SVP & Global Head of Immuno-Oncology Translational Innovation Platform, EMD Serono


  • Resistance Mechanisms for Immune Checkpoint Therapy

    Jianjun Gao
    Jianjun Gao, MD, PhD

    Assistant Professor, Genitourinary Medical Oncology, MD Anderson Cancer Center


  • Immuno Resistance and Beta2 Microglobulin Mutations

    Forde Patrick
    Patrick Forde, MBBCh

    Assistant Professor of Oncology, Johns Hopkins University

  • 3:00 pm

  • Afternoon Break


  • NOVEL TECHNOLOGIES AND EMERGING BIOMARKERS PLENARY SESSION

    Plenary Chair:

    Kenneth Hance
    Kenneth Hance, PhD, MPH

    Director, Antibody Therapies, Immuno-Oncology & Combinations Discovery Performance Unit, GlaxoSmithKline

  • 3:45 pm

  • Biomarker Standardization

    david wholley
    David Wholley, MPhil

    Director, Research Partnerships Division, Foundation for the National Institutes of Health


  • Different Platforms to make Bi-Specific Antibodies

    Kenneth Hance
    Kenneth Hance, PhD, MPH

    Director, Antibody Therapies, Immuno-Oncology & Combinations Discovery Performance Unit, GlaxoSmithKline


  • Engaging the Innate Immune System to Enhance the Power of IO Therapy

    Anne Assmus
    Anne Assmus, PhD

    VP,  Business Development, Affimed, Inc


  • Predictive Relationships Between TCR Repertoires and Efficacy


  • Using Next Gen Sequencing for Selecting Patients for Combination Immunotherapy Trials

    Phil Stephens
    Phil Stephens, PhD

    Chief Scientific Officer, Foundation Medicine

  • Multiplexing IHC Assays


  • IO Combination Sources and Solutions

    Christelle Johnson
    Christelle Johnson, MS, PhD

    Field Applications Scientist, Personalis

    Stephen_Russell
    Stephen J Russell, MD, PhD

    Founder, Director, CEO & President, Vyriad
  • 6:30 pm

  • Networking Reception

2017 Agenda

  • 8:30 am

  • Registration & Breakfast

  • 9:00 am

  • Co-chair’s Opening Remarks

    Axel Hoos
    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GlaxoSmithKline

    Patrick Hwu
    Patrick Hwu, MD

    Head, Division of Cancer Medicine, Department Chair, Melanoma Medical Oncology Department Chair, Sarcoma Medical Oncology, MD Anderson Cancer Center

    Ian McCaffery
    Ian McCaffery, PhD

    VP Translational Sciences, Corvus Pharmaceuticals


  • CLINICAL COMBINATION IMMUNOTHERAPY PLENARY SESSION

    Plenary Chair:

    Ian McCaffery
    Ian McCaffery,
    PhD
    VP Translational Sciences, Corvus Pharmaceuticals

  • 9:15 am

  • Emerging Key Combinations with Pembrolizumab in Late Stage Development


    Roy Baynes, MD, PhD

    SVP, Global Clinical Development, Merck Research Labs


  • Combination Immunotherapy for Lung Cancer

    Julie Hambleton
    Julie Hambleton,
    MD
    VP, Head US Medical, Bristol-Myers Squibb


  • Clinical Trial Designs for IO Combinations

    Susan Slovin
    Susan Slovin, MD, PhD

    Attending Physician, Genitourinary Oncology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center


  • Combination Immunotherapy for Metastatic Bladder Cancer

    Arjun Balar
    Arjun V Balar
    , MD
    Director of GU Medical Oncology, Perlmutter Cancer Center, NYU Langone


  • Morning Networking Break


  • Immune Targeting in Gastrointestinal (GI) Malignancies

    Neil Segal
    Neil Segal, MD, PhD

    Medical Oncologist, Clinical Director, Immunotherapeutics Group, Memorial Sloan Kettering Cancer Center

  • Combination Immunotherapy in Renal Cell Carcinoma


    Chung-Han Lee,
    MD, PhD
    Medical Oncologist, Memorial Sloan Kettering Cancer Center


  • Hematology Data for Combinations

    Ezo Gruyters
    Ezogelin Oflazoglu-Gruyters, PhD
    Executive Director and Global Program Leader, Celgene


  • CPI444 Clinical Activity and Translational Insights into a Novel Checkpoint Pathway

    Ian McCaffery
    Ian McCaffery,
    PhD
    VP Translational Sciences, Corvus Pharmaceuticals

  • 12:15 pm

  • Lunch


  • BUSINESS ASPECTS FOR COMBINATION IMMUNOTHERAPY PLENARY SESSION

    Plenary Chair:


    Asthika Goonewardene, MBA

    Senior Biotech Analyst, Bloomberg Intelligence

  • 1:15 pm

  • Novel Paradigms for Academic/Industry Partnerships

    Ferran Prat
    Ferran Prat, PhD, JD

    VP, Strategic Industry Ventures, MD Anderson Cancer Center


  • PANEL: Partnerships and Deals Between Pharma and Small Biotechs to Enable Co-development of Combinations

    Moderator:

    Axel Hoos
    Axel Hoos, MD, PhD

    SVP, Oncology R&D, GlaxoSmithKline

    Panelists:

    Anne Assmus
    Anne Assmus, PhD

    VP,  Business Development, Affimed, Inc


    Kimberly Freeman

    VP, Commercial Strategy & Planning, Adaptimmune


    Alessandra Polara

    Business Development & Licensing Director, Roche Partnering Oncology, Genentech

    Benjamin Thorner
    Benjamin (Ben) Thorner

    SVP and Head of Business Development & Licensing, Merck Research Laboratories


  • Investor Roundtable: Evaluating the Combination Immunotherapy Investment Ecosystem

    Moderator:


    Asthika Goonewardene, MBA
    Senior Biotech Analyst, Bloomberg Intelligence

    Panelists:

    Gilles Dufour
    Gilles Dufour, PhD

    Associate, RA Capital

    Axel Hoos
    Axel Hoos, MD, PhD
    SVP, Oncology R&D, GlaxoSmithKline

    Brad Loncar
    Brad Loncar

    CEO, Loncar Investments

    Carlo Rizzuto
    Carlo Rizzuto, PhD
    Partner, Versant Ventures


    Mark Simon, MBA

    Partner, Torreya Partners

  • 3:15 pm

  • Afternoon Break


  • CLINICAL MANIFESTATIONS OF IMMUNOLOGICAL TOXICITIES

    Plenary Chair:

    Joyson Karakunnel
    Joyson Karakunnel, MD, MSc, FACP

    Medical Director & Advisor, Parker Institute for Cancer Immunotherapy and VP & Head of Clinical Development, Arcus Biosciences

  • 3:30 pm

  • Unifying Treatment Algorithms for Immunological Toxicity

    Joyson Karakunnel
    Joyson Karakunnel, MD, MSc, FACP

    Medical Director & Advisor, Parker Institute for Cancer Immunotherapy and VP & Head of Clinical Development, Arcus Biosciences


  • Toxicity of Checkpoint Modulating Drugs Across the Spectrum


  • Late Onset of Toxicities after Checkpoint Modulation

    Adi Diab
    Adi Diab, MD

    Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center


  • CAR-T Associated Neurotoxicity: Pathophysiologic Learnings & Prophylactic Strategies

    Hyam Levitsky
    Hyam Levitsky, MD

    EVP, Chief Scientific Officer, Juno Therapeutics


  • Updates on CD19 CAR Toxicities and How They are Managing Them with Future Combinations

  • 5:15 pm

  • End of Conference